Form 4: Longitude Capital Sells RPID Shares Under 10b5-1 Plan

Longitude Capital Partners II, a 10% owner and director, reported the sale of 49,000 shares of Rapid Micro Biosystems Class A Common Stock at $3.8794 per share, executed under a 10b5-1 plan.

Summary

• Longitude Capital Partners II, LLC, along with affiliated entities and individuals including Patrick G. Enright and Juliet Tammenoms Bakker, reported a sale of Class A Common Stock of Rapid Micro Biosystems, Inc. (RPID).
• The transaction involved the disposition of 49,000 shares at a price of $3.8794 per share.
• The sale occurred on February 4, 2026, and was executed pursuant to a Rule 10b5-1(c) pre-arranged trading plan.
• Following this transaction, Longitude Prime Fund, L.P. directly holds 0 shares, while Longitude Venture Partners II, L.P. indirectly holds 4,029,245 shares.
• The reporting persons are identified as 10% owners and directors of Rapid Micro Biosystems, Inc.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a moderately negative signal due to a significant insider sale by a 10% owner and director, even though it was pre-planned under a 10b5-1 plan. While pre-planned sales reduce the immediate negative implication, they still represent a reduction in insider holdings.

Positives

• The transaction was executed under a Rule 10b5-1(c) plan, indicating a pre-arranged sale rather than a reaction to immediate market conditions or new material non-public information.

Negatives

• A 10% owner and director sold 49,000 shares, which can be interpreted as a reduction in insider confidence or a need for liquidity by the reporting entity.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that insider sales, even those executed under a 10b5-1 plan, are often scrutinized by investors for potential signals regarding management's perception of future company performance. In the biotechnology and diagnostics industry, such sales by significant institutional investors like Longitude Capital, a venture capital firm specializing in healthcare, can sometimes precede periods of consolidation or strategic shifts, though the 10b5-1 plan suggests a pre-determined liquidity event rather than a reactive move.

Related Party Transactions

• The sale of 49,000 shares of Class A Common Stock by Longitude Capital Partners II, LLC and its affiliated entities and individuals, who are 10% owners and directors of Rapid Micro Biosystems, Inc.

Stakeholder Impact

• Shareholders: May interpret the insider sale as a reduction in confidence, potentially leading to downward pressure on the stock price, despite the 10b5-1 plan.
• Management: The transaction by a director and 10% owner could prompt questions regarding the company's near-term prospects, even with the pre-arranged nature of the sale.

Key Dates

Recommendation

While the sale by a 10% owner and director is generally a negative signal, the fact that it was executed under a pre-arranged 10b5-1 plan mitigates the immediate concern of a reactive sale based on new negative information. Investors should monitor future insider activity and company performance, but this single pre-planned transaction does not warrant an immediate 'sell' recommendation without further context or additional negative catalysts. A 'hold' position is prudent to observe further developments.

Keywords

Rapid Micro Biosystems, RPID, Longitude Capital, Insider Sale, Form 4, Beneficial Ownership, 10b5-1 Plan, Director Transaction, 10% Owner